Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil

A 39‐year‐old female patient with systemic lupus erythematosus was treated with terbinafine for onychomycosis. After only 7 days of treatment with 250 mg terbinafine, a widespread severe erythematous eruption developed. The results of clinical, histological and immunofluorescent examinations confirm...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 2006-03, Vol.45 (3), p.320-322
Main Authors: Cetkovská, Petra, Pizinger, Karel
Format: Article
Language:English
Subjects:
Acute Disease
Adult
Antifungal Agents - adverse effects
Biological and medical sciences
Cyclosporine - therapeutic use
Dermatology
Female
Humans
Immunosuppressive Agents - therapeutic use
Lupus Erythematosus, Systemic - chemically induced
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - drug therapy
Medical sciences
Methylprednisolone - therapeutic use
Mycophenolic Acid - analogs & derivatives
Mycophenolic Acid - therapeutic use
Naphthalenes - adverse effects
Onychomycosis - complications
Onychomycosis - drug therapy
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 39‐year‐old female patient with systemic lupus erythematosus was treated with terbinafine for onychomycosis. After only 7 days of treatment with 250 mg terbinafine, a widespread severe erythematous eruption developed. The results of clinical, histological and immunofluorescent examinations confirmed the diagnosis of coexisting subacute and systemic lupus erythematosus. The patient was treated with drug withdrawal and administration of cyclosporine and methylprednisolone. One year later, mycophenolate mofetil was successfully used. Exacerbation or induction of lupus erythematosus is an extremely rare cutaneous side‐effect of terbinafine. Patients with lupus erythematosus should be advised about the risk of some drugs that might exacerbate their disease.
ISSN:0011-9059
1365-4632
DOI:10.1111/j.1365-4632.2004.02472.x